Literature DB >> 2479049

Infected abdominal tumors: percutaneous catheter drainage.

P R Mueller1, E M White, M Glass-Royal, R K Zeman, S Saini, S G Silverman, P F Hahn, J F Simeone.   

Abstract

Sixteen patients underwent percutaneous catheter drainage of infected primary (n = 9) or metastatic (n = 7) abdominal tumors. Twelve of the patients improved clinically, as evidenced by defervescence and decrease or normalization of leukocytosis. Four patients did not respond to catheter drainage and required surgery. Three of the twelve who improved underwent operations for attempts at surgical cure or debulking of tumor volume despite an initial "good" response to percutaneous drainage. Of the nine patients who did not undergo surgery after percutaneous drainage, four underwent catheter removal after 5 weeks of drainage and had no recurrence of infection, two remained alive with the catheter in place up to 8 months and 1 year after drainage, and two died with the catheter in place. One patient had the catheter removed inadvertently after 3 weeks of drainage and had recurrences that required replacement of the catheter until his death. The major differences between drainage of necrotic tumors and drainage of standard abscesses were the need for surgery in the majority of the cases and the fact that patients needed the catheters for continued palliation until their death.

Entities:  

Mesh:

Year:  1989        PMID: 2479049     DOI: 10.1148/radiology.173.3.2479049

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Percutaneous drainage and management of fluid collections associated with necrotic or cystic tumors in the abdomen and pelvis.

Authors:  David H Ballard; Mahati Mokkarala; Horacio B D'Agostino
Journal:  Abdom Radiol (NY)       Date:  2019-04

Review 2.  Approaches to the difficult drainage and biopsy.

Authors:  Shaunagh McDermott; Diane A Levis; Ronald S Arellano
Journal:  Semin Intervent Radiol       Date:  2012-12       Impact factor: 1.513

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.